MPS Limited Acquires Unbound Medicine for USD 16.5 Million
MPS Limited's subsidiary, MPS North America LLC, will acquire 100% of Unbound Medicine, Inc. for USD 16.50 Million. The deal is expected to close by February 10, 2026. This acquisition marks MPS' entry into the healthcare technology sector, complementing its existing digital publishing and learning platform strengths.
The acquisition represents a significant strategic expansion into a new, high-growth vertical, aligning with the company's long-term revenue and growth ambitions.
The acquisition is strategic, marks entry into a high-growth segment, and is expected to create significant synergies and value for MPS Limited.
MPS Limited, through its wholly-owned subsidiary MPS North America LLC, has entered into a Stock Purchase Agreement (SPA) to acquire 100% stake in Unbound Medicine, Inc., a US-based healthcare learning technology company. The total consideration for the acquisition is USD 16.50 Million, subject to customary adjustments. The acquisition is expected to be completed on or before February 10, 2026. This strategic move marks MPS Limited's entry into the healthcare and medical information technology segment, a high-growth vertical complementary to its core strengths. Unbound Medicine, founded in 1999, provides mobile-first and AI-enabled clinical decision support and medical education platforms to over 480 institutional customers, primarily in the United States and Canada. The company operates on a subscription-led model with approximately 97% gross retention. The acquisition aligns with MPS Limited's long-term growth strategy to exceed INR 1,500 crore in revenue by FY28 by investing in scalable, profitable businesses accelerated through technology and data. Key synergies include strategic entry into healthcare learning technologies, expanded platform-led solutions, revenue synergies via cross-selling, innovation acceleration through MPS Labs, operational scale, and a resilient recurring revenue base. The acquisition does not involve related party transactions. The transaction is being undertaken in compliance with the Foreign Exchange Management Act, 1999, and applicable RBI regulations.
What to do with a filing like this
MPS Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by MPS Limited. Read the original for the full detail.